Lannett On Track To Launch Insulin Glargine By 2023

Company Expects Pivotal Trial For Lantus Biosimilar To Start In 2022

 
• By Akriti Seth
feedback
Lannett receives positive feedback from FDA for its biosimilar insulin glargine • Source: Shutterstock

More from Biosimilars

More from Products